Clinical Research News | Metabolic Research Institute

Chronic Kidney Disease and Itchy Skin

Have you been diagnosed with chronic kidney disease and moderate to severe itchy skin?

Consider a clinical research study for chronic kidney disease and itchy skin.

Researchers are testing an investigational oral medication for itchy skin in people with chronic kidney disease.

For more information, or to see if you qualify to participate in this clinical research trial, call Metabolic Research Institute Inc. (561) 802-3060, ext. 8036 or visit: metabolic-institute.com/itchy-skin

Fatty Liver Disease (NASH) Study

Living with Fatty Liver Disease (NASH)?

Learn more about a study for nonalcoholic fatty liver disease (NASH).

This study is researching the safety and effectiveness of an investigational drug in people with a confirmed or suspected diagnosis of (NASH).

Join the search for an effective therapy for fatty liver disease.

For more information, call Metabolic Research Institute: (561) 802-3060, ext. 8036 or visit: https://www.metabolic-institute.com/nash-study/

Low Testosterone Clinical Study for Men

Have you been diagnosed with low testosterone?

Consider a clinical research study.

We are looking for men 18 years of age or older who are diagnosed with low testosterone to participate in a clinical research study.

Researchers are studying the effect of testosterone treatment on blood pressure in men diagnosed with low testosterone.

For more information, or to see if you qualify to participate in this study, call Metabolic Research Institute Inc. (561) 802-3060, ext. 8036 or visit: https://www.metabolic-institute.com/low-testosterone/

DM2 on Metformin Clinical Study

Are you taking Metformin to control your Type 2 Diabetes?
Consider a clinical research study. No health insurance required.

We are enrolling volunteers in a clinical research study evaluating the safety and efficacy of Metformin DR in T2DM patients with varying degrees of kidney function.

For more information, or to see if you qualify to participate in this study, call Metabolic Research Institute, Inc. (561) 802-3060, ext. 8036 or visit: https://www.metabolic-institute.com/metformin/

What is NASH (non-alcoholic steatohepatitis)?

Non-alcoholic steatohepatitis, NASH, is the severe form of a chronic liver disease called Non-Alcoholic Fatty Liver Disease (NAFLD).

Join the search for an effective treatment therapy. A clinical study is enrolling now in West Palm Beach, Florida.

For more information, or to learn if you may qualify to participate in this study, call Metabolic Research Institute (561) 802-3060, ext. 8036 or visit: https://www.metabolic-institute.com/what-is-nash/

Oral Insulin: Not Your Grandmother’s Insulin

Barry S. Horowitz, M.D., F.A.C.P.

February 7, 2022

Many diabetics have fears about taking insulin: they don’t want to take a shot; they will gain weight; and they will develop complications of diabetes. These concerns really have no basis in reality. However, a new oral form of insulin is being developed by a company called Oramed that could be a nice addition to our toolbox for treating type 2 diabetes.

It is important to understand that by the time someone is diagnosed with diabetes, they have lost about 50% of the pancreas’ ability to make insulin. The insulin production continues to decrease over time and many type 2 diabetics ultimately need to take insulin despite their best efforts to control their sugars. Thus, insulin plays an important role in the management of diabetes and should not be looked at negatively.

Insulin will not cause weight gain if it is properly managed. The reason some people think they might develop complications of diabetes with insulin (e.g. amputations, etc.) is that they have witnessed relatives who have experienced this. However, this is not due to taking insulin but rather the fact that their diabetes was probably under poor control for a long period of time such that complications were developing and the insulin was given much too late.

Insulin is injected because it is a protein that cannot be absorbed in the intestine. However, Oramed has figured out how to encapsulate insulin in a matrix such that it can be absorbed. This will not give the high levels of insulin that are achieved with injection, but will give sufficient levels to suppress the liver making sugar and decrease blood sugar levels. In addition to not having to take an injection, there is no weight gain. Please contact the Metabolic Research Institute (561) 802-3060, ext. 8036 for more information about a clinical trial we are conducting with oral insulin.

« Older Entries

Next Entries »